About Tirzepatide Meds — Independent Research Digest
About this site
Tirzepatide Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature and regulatory record on tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain modifier 'Meds' is editorial framing — it positions this site relative to the literature on a compound with approved medical indications, not a claim that this site sells, prescribes, or dispenses medication. We are explicit about this distinction because the compound is a prescription medicine, and we want readers to be clear that this site is a reading desk for the research, not a pharmacy or a clinical service.
What this site covers
Tirzepatide received three U.S. FDA approvals: for type 2 diabetes (May 2022), chronic weight management (November 2023), and obstructive sleep apnea. The compound is the first approved dual incretin agonist — a single synthetic peptide that activates both the GIP and GLP-1 receptors — and has generated one of the largest clinical trial programmes in metabolic medicine in recent years: the SURPASS and SURMOUNT programmes, plus ongoing trials in heart failure, liver disease, and other conditions.
This site documents that research record. Each quantitative claim on this site is cited to a numbered reference from the peer-reviewed literature, the FDA prescribing information, or established clinical guideline sources. The what is tirzepatide and Tirzepatide research pages cover the mechanism and trial evidence. The Tirzepatide effects and tirzepatide side effects pages document the human-reported and trial-documented effects and safety profile. The dosage page describes the dosing protocol as studied in trials.
Editorial standards
Every quantitative claim on this site is cited to a numbered source in the references list. Findings are attributed to the specific study that produced them. Where evidence is incomplete, uncertain, or based on animal data rather than human data, that is stated explicitly — using plain-English labels such as 'rodent data, human significance not established,' 'meta-analysis,' or 'anecdotal, not clinical evidence.'
We do not invent citations. We do not use competitor brand names. We do not provide dosing recommendations. This site is a literature digest, read straight from the published record. Readers who need clinical guidance on tirzepatide should consult a licensed physician or pharmacist.